Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?
Foffano L, Vida R, Piacentini A, Molteni E, Cucciniello L, Da Ros L, Silvia B, Cereser L, Roncato R, Gerratana L, Puglisi F. Foffano L, et al. Among authors: gerratana l. Expert Rev Anticancer Ther. 2024 Aug;24(8):679-691. doi: 10.1080/14737140.2024.2362173. Epub 2024 Jul 1. Expert Rev Anticancer Ther. 2024. PMID: 38855809 Review.
Hype or hope? The strange case of platinum salts' renaissance in breast cancer.
Corvaja C, Garutti M, Gerratana L, Pelizzari G, Puglisi F. Corvaja C, et al. Among authors: gerratana l. Expert Rev Anticancer Ther. 2019 Dec;19(12):1005-1008. doi: 10.1080/14737140.2019.1699066. Epub 2019 Dec 2. Expert Rev Anticancer Ther. 2019. PMID: 31775005 No abstract available.
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle.
Gerratana L, Bonotto M, Bozza C, Ongaro E, Fanotto V, Pelizzari G, Puglisi F. Gerratana L, et al. Expert Opin Biol Ther. 2017 Mar;17(3):365-374. doi: 10.1080/14712598.2017.1282944. Epub 2017 Jan 30. Expert Opin Biol Ther. 2017. PMID: 28092723 Review.
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer.
Gerratana L, Basile D, Franzoni A, Allegri L, Viotto D, Corvaja C, Bortot L, Bertoli E, Buriolla S, Targato G, Da Ros L, Russo S, Bonotto M, Belletti B, Baldassarre G, Damante G, Puglisi F. Gerratana L, et al. Front Oncol. 2020 Sep 18;10:550185. doi: 10.3389/fonc.2020.550185. eCollection 2020. Front Oncol. 2020. PMID: 33072577 Free PMC article.
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study.
Basile D, Gerratana L, Corvaja C, Pelizzari G, Franceschin G, Bertoli E, Palmero L, Zara D, Alberti M, Buriolla S, Da Ros L, Bonotto M, Mansutti M, Spazzapan S, Cinausero M, Minisini AM, Fasola G, Puglisi F. Basile D, et al. Among authors: gerratana l. Breast. 2021 Jun;57:104-112. doi: 10.1016/j.breast.2021.02.015. Epub 2021 Mar 12. Breast. 2021. PMID: 33812267 Free PMC article.
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?
Buono G, Gerratana L, Bulfoni M, Provinciali N, Basile D, Giuliano M, Corvaja C, Arpino G, Del Mastro L, De Placido S, De Laurentiis M, Cristofanilli M, Puglisi F. Buono G, et al. Among authors: gerratana l. Cancer Treat Rev. 2019 Feb;73:73-83. doi: 10.1016/j.ctrv.2019.01.004. Epub 2019 Jan 11. Cancer Treat Rev. 2019. PMID: 30682661 Free article. Review.
Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer.
Gerratana L, Davis AA, Zhang Q, Basile D, Rossi G, Strickland K, Franzoni A, Allegri L, Mu Z, Zhang Y, Flaum LE, Damante G, Gradishar WJ, Platanias LC, Behdad A, Yang H, Puglisi F, Cristofanilli M. Gerratana L, et al. JCO Precis Oncol. 2021 Jun 8;5:943-952. doi: 10.1200/PO.20.00345. eCollection 2021 Jun. JCO Precis Oncol. 2021. PMID: 34136741 Free PMC article.
106 results